-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 11, 2024

MIRASOL trial and DESTINY-PanTumor02 Trial Overview

Ronald D. Alvarez, MD, MBA, gives an analysis of the MIRASOL and DESTINY-PanTumor02 trials, including a comparison of study arms and discussion of HER2/neu targeting.

Episodes in this series

EP. 1 NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

EP. 1 NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

Video 1 - "NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer"

EP. 2 NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

EP. 3 Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

EP. 4 MIRASOL trial and DESTINY-PanTumor02 Trial Overview

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

EP. 5 Tailored Therapy: Decision Making for Ovarian Cancer Treatment

Video 5 - "Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment"

EP. 6 Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment

Video 6 - "Closing Thoughts on the Current Ovarian Cancer Treatment Landscape"

EP. 7 Closing Thoughts on the Current Ovarian Cancer Treatment Landscape

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

Ebola Cases Top 1700 as Unpaid Health Workers Strike

FDA Expands Approval for VWD Prophylaxis in Children Younger Than 6

Quest Adds Haystack MRD to OncoEMR for Community Oncology

Gene Therapy Could Ease Wet AMD's Injection Burden: Carl Regillo, MD

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers